|
gptkbp:instanceOf
|
gptkb:drug
cyclin-dependent kinase inhibitor
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EF03
|
|
gptkbp:brand
|
gptkb:Verzenio
|
|
gptkbp:CASNumber
|
1231929-97-7
|
|
gptkbp:chemicalFormula
|
C27H32F2N8
|
|
gptkbp:combines
|
gptkb:fulvestrant
aromatase inhibitors
|
|
gptkbp:developer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abemaciclib
|
|
gptkbp:indication
|
HER2-negative breast cancer
hormone receptor-positive breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CDK4/6 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
506.6 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
96.3%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
fatigue
infections
neutropenia
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:Verzenio
gptkb:advanced_hormone_receptor-positive,_HER2-negative_breast_cancer
|
|
gptkbp:bfsLayer
|
6
|